Skip to main content
Premium Trial:

Request an Annual Quote

PGDx Liquid Biopsy Assay Gets CE Marking

NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that its PGDx Elio Plasma Resolve liquid biopsy assay has received CE marking.

The in vitro diagnostic uses next-generation sequencing to detect single-nucleotide variants, small insertions and deletions, amplifications, rearrangements, and microsatellite instability in circulating cell-free DNA isolated from plasma samples to guide therapy selection for cancer patients. PGDx also markets a tissue-based version of the test.

"The CE mark of PGDx Elio Plasma Resolve allows us to bring this product to Europe, providing greater access to patients who could benefit from genomic testing, particularly those who cannot provide tissue samples," PGDx CEO Doug Ward said in a statement.

In mid-2018, the PGDx Elio Plasma Resolve received a Breakthrough Device Designation from the Food and Drug Administration's Center for Device and Radiological Health. And, in October, Baltimore, Maryland-based PGDx said that Bristol-Myers Squibb had adopted the test for use in a clinical trial evaluating two of its cancer drugs in patients with certain genetic mutations.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.